Edgestream Partners, L.P. Krystal Biotech, Inc. Transaction History

Edgestream Partners, L.P.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 13, 2025	BUY	$123.36 - $181.0 $2.43 Million - $3.56 Million	19,678 New	19,678 $2.7 Million
Q4 2024 Feb 06, 2025	SELL	$156.64 - $199.61 $1.32 Million - $1.69 Million	-8,447 Reduced 26.19%	23,810 $3.73 Million
Q3 2024 Nov 14, 2024	BUY	$174.7 - $213.66 $5.64 Million - $6.89 Million	32,257 New	32,257 $5.87 Million

325

25M

241K

625K

Ticker KRYS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,664,300
Market Cap $5.29B
Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...

Get notified when there are updates to the investment portfolio of Edgestream Partners, L.P., based on Form 13F filings with the SEC.

Stay updated on Edgestream Partners, L.P. with notifications on news.